Adaptimmune Therapeutics plc Overview
Latest ROE for Adaptimmune Therapeutics plc: 239.23% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow239.23%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Adaptimmune Therapeutics plc's return on equity stands at 239.23%. That is above the Healthcare sector average of -75.59%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Adaptimmune Therapeutics plc sits higher the Healthcare benchmark (-75.59%) with a ROE of 239.23%. That is roughly 416.5% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 239.23% for Adaptimmune Therapeutics plc means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Adaptimmune Therapeutics plc's ROE evolved across reporting periods, while the comparison chart places ADAPY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Adaptimmune Therapeutics plc's reading of 239.23% (sector avg -75.59%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
